抗IgE疗法在特应性皮炎患者中的疗效。 - Suppr

Suppr

超能文献

Efficacy of anti-IgE therapy in patients with atopic dermatitis.

作者信息

Vigo Paul G, Girgis Khaled R, Pfuetze Bruce L, Critchlow Michael E, Fisher Joe, Hussain Iftikhar

出版信息

J Am Acad Dermatol. 2006 Jul;55(1):168-70. doi: 10.1016/j.jaad.2005.12.045.

DOI:10.1016/j.jaad.2005.12.045

PMID:16781320

Abstract

摘要

相似文献

Efficacy of anti-IgE therapy in patients with atopic dermatitis.

J Am Acad Dermatol. 2006 Jul;55(1):168-70. doi: 10.1016/j.jaad.2005.12.045.

Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels.

J Allergy Clin Immunol. 2007 Nov;120(5):1223-5. doi: 10.1016/j.jaci.2007.08.060. Epub 2007 Oct 22.

Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study.

J Dtsch Dermatol Ges. 2010 Dec;8(12):990-8. doi: 10.1111/j.1610-0387.2010.07497.x.

Anti-immunoglobulin e in the treatment of refractory atopic dermatitis.

South Med J. 2010 Jun;103(6):554-8. doi: 10.1097/SMJ.0b013e3181de0cf6.

Anti-CD20 (rituximab) treatment for atopic eczema.

J Allergy Clin Immunol. 2008 Jun;121(6):1515-6; author reply 1516-7. doi: 10.1016/j.jaci.2008.03.007. Epub 2008 Apr 14.

Failure of omalizumab for treatment of severe adult atopic dermatitis.

J Am Acad Dermatol. 2005 Aug;53(2):338-40. doi: 10.1016/j.jaad.2005.02.014.

Omalizumab (an anti-IgE antibody) in the treatment of severe atopic eczema.

J Investig Allergol Clin Immunol. 2011;21(5):416-7.

Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody.

Dermatol Online J. 2005 Mar 1;11(1):2.

Anti-CD20 (rituximab) treatment improves atopic eczema.

J Allergy Clin Immunol. 2008 Jan;121(1):122-8. doi: 10.1016/j.jaci.2007.11.016.

Wanted: A study with omalizumab to determine the role of IgE-mediated pathways in atopic dermatitis.

J Am Acad Dermatol. 2006 Sep;55(3):540-1; author reply 541-2. doi: 10.1016/j.jaad.2006.01.037.

引用本文的文献

Oral and topical administration of a geranyl acetophenone attenuates DNCB-induced atopic dermatitis-like skin lesions in BALB/c mice.

Sci Rep. 2024 Jul 31;14(1):17623. doi: 10.1038/s41598-024-66601-0.

Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis.

BioDrugs. 2021 Jul;35(4):401-415. doi: 10.1007/s40259-021-00490-x. Epub 2021 Jul 2.

Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence.

World Allergy Organ J. 2021 Mar 19;14(3):100519. doi: 10.1016/j.waojou.2021.100519. eCollection 2021 Mar.

Biological therapies for atopic dermatitis: An update.

Exp Ther Med. 2019 Feb;17(2):1061-1067. doi: 10.3892/etm.2018.6989. Epub 2018 Nov 19.

Systemic therapy of atopic dermatitis.

Allergol Select. 2017 Aug 4;1(1):1-8. doi: 10.5414/ALX01285E. eCollection 2017.

The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus.

Inflamm Regen. 2017 Jun 5;37:14. doi: 10.1186/s41232-017-0044-7. eCollection 2017.

Update on oral immunotherapy for egg allergy.

Hum Vaccin Immunother. 2017 Oct 3;13(10):2452-2461. doi: 10.1080/21645515.2017.1339844.

The role of anti-IgE (omalizumab/Xolair) in the management of severe recalcitrant paediatric atopic eczema (ADAPT): statistical analysis plan.

Trials. 2017 May 23;18(1):231. doi: 10.1186/s13063-017-1976-6.

Systemic Treatment of Adult Atopic Dermatitis: A Review.

Dermatol Ther (Heidelb). 2017 Mar;7(1):1-23. doi: 10.1007/s13555-016-0170-1. Epub 2016 Dec 26.

Systemic Agents for Severe Atopic Dermatitis in Children.

Paediatr Drugs. 2015 Dec;17(6):449-57. doi: 10.1007/s40272-015-0150-4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Efficacy of anti-IgE therapy in patients with atopic dermatitis.

J Am Acad Dermatol. 2006 Jul;55(1):168-70. doi: 10.1016/j.jaad.2005.12.045.

Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels.

J Allergy Clin Immunol. 2007 Nov;120(5):1223-5. doi: 10.1016/j.jaci.2007.08.060. Epub 2007 Oct 22.

Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study.

J Dtsch Dermatol Ges. 2010 Dec;8(12):990-8. doi: 10.1111/j.1610-0387.2010.07497.x.

Anti-immunoglobulin e in the treatment of refractory atopic dermatitis.

South Med J. 2010 Jun;103(6):554-8. doi: 10.1097/SMJ.0b013e3181de0cf6.

Anti-CD20 (rituximab) treatment for atopic eczema.

J Allergy Clin Immunol. 2008 Jun;121(6):1515-6; author reply 1516-7. doi: 10.1016/j.jaci.2008.03.007. Epub 2008 Apr 14.

Failure of omalizumab for treatment of severe adult atopic dermatitis.

J Am Acad Dermatol. 2005 Aug;53(2):338-40. doi: 10.1016/j.jaad.2005.02.014.

Omalizumab (an anti-IgE antibody) in the treatment of severe atopic eczema.

J Investig Allergol Clin Immunol. 2011;21(5):416-7.

Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody.

Dermatol Online J. 2005 Mar 1;11(1):2.

Anti-CD20 (rituximab) treatment improves atopic eczema.

J Allergy Clin Immunol. 2008 Jan;121(1):122-8. doi: 10.1016/j.jaci.2007.11.016.

Wanted: A study with omalizumab to determine the role of IgE-mediated pathways in atopic dermatitis.

J Am Acad Dermatol. 2006 Sep;55(3):540-1; author reply 541-2. doi: 10.1016/j.jaad.2006.01.037.

引用本文的文献

Oral and topical administration of a geranyl acetophenone attenuates DNCB-induced atopic dermatitis-like skin lesions in BALB/c mice.

Sci Rep. 2024 Jul 31;14(1):17623. doi: 10.1038/s41598-024-66601-0.

Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis.

BioDrugs. 2021 Jul;35(4):401-415. doi: 10.1007/s40259-021-00490-x. Epub 2021 Jul 2.

Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence.

World Allergy Organ J. 2021 Mar 19;14(3):100519. doi: 10.1016/j.waojou.2021.100519. eCollection 2021 Mar.

Biological therapies for atopic dermatitis: An update.

Exp Ther Med. 2019 Feb;17(2):1061-1067. doi: 10.3892/etm.2018.6989. Epub 2018 Nov 19.

Systemic therapy of atopic dermatitis.

Allergol Select. 2017 Aug 4;1(1):1-8. doi: 10.5414/ALX01285E. eCollection 2017.

The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus.

Inflamm Regen. 2017 Jun 5;37:14. doi: 10.1186/s41232-017-0044-7. eCollection 2017.

Update on oral immunotherapy for egg allergy.

Hum Vaccin Immunother. 2017 Oct 3;13(10):2452-2461. doi: 10.1080/21645515.2017.1339844.

The role of anti-IgE (omalizumab/Xolair) in the management of severe recalcitrant paediatric atopic eczema (ADAPT): statistical analysis plan.

Trials. 2017 May 23;18(1):231. doi: 10.1186/s13063-017-1976-6.

Systemic Treatment of Adult Atopic Dermatitis: A Review.

Dermatol Ther (Heidelb). 2017 Mar;7(1):1-23. doi: 10.1007/s13555-016-0170-1. Epub 2016 Dec 26.

Systemic Agents for Severe Atopic Dermatitis in Children.

Paediatr Drugs. 2015 Dec;17(6):449-57. doi: 10.1007/s40272-015-0150-4.